Ascentage Pharma posts 29% first-half 2026 revenue rise to US$44.5 million, citing Olverembatinib sales growth
AI Market Summary
Ascentage Pharma reported 1H26 unaudited results with revenue up 29% to US$44.5m, driven by Olverembatinib sales and broader formulary coverage, alongside continued global Phase III trial progress. However, operating costs rose sharply (R&D and selling/distribution), widening the net loss and reducing cash balances, highlighting ongoing funding and execution sensitivity. The update is largely idiosyncratic and should have limited broader cross-asset impact.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.25%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Ascentage Pharma reported unaudited results for the first half of 2026, with revenue up 29% year over year to US$44.5 million, driven mainly by higher Olverembatinib sales. As of June 30, 2026, Olverembatinib had been added to formularies at 879 DTP pharmacies and hospitals. Hospital coverage rose 34% year over year to 394 hospitals.
